Integrative development of a TLR8 agonist for ovarian cancer chemoimmunotherapy

Clinical Cancer Research

Volumn 23, Issue 8, 2017, Pages 1955-1966

  Monk, Bradley J ^a   Facciabene, Andrea ^b   Brady, William E ^c   Aghajanian, Carol A ^d   Fracasso, Paula M ^e   Walker, Joan L ^f   Lankes, Heather A ^c   Manjarrez, Kristi L ^g   Danet Desnoyers, Gwenn Äel H ^b   Bell McGuinn, Katherine M ^d   McCourt, Carolyn K ^h   Malykhin, Alexander ^b   Hershberg, Robert M ^g   Coukos, George ^b,i  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e UNIVERSITY OF VIRGINIA   (United States)

^f UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^g VentiRx Pharmaceuticals   (United States)

^h WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; MOTOLIMOD; PACLITAXEL; ANTINEOPLASTIC AGENT; BENZAZEPINE DERIVATIVE; MACROGOL DERIVATIVE; TLR8 PROTEIN, HUMAN; TOLL LIKE RECEPTOR 8; VTX-2337;

ABDOMINAL PAIN; ALOPECIA; ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANOREXIA; ANXIETY DISORDER; ARTHRALGIA; ARTICLE; BACKACHE; CANCER IMMUNOTHERAPY; CHILL; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG POTENTIATION; DRUG RESPONSE; DYSPNEA; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; HYPERTENSION; HYPOALBUMINEMIA; HYPOKALEMIA; HYPONATREMIA; IMMUNE RESPONSE; IN VIVO STUDY; INJECTION SITE REACTION; INNATE IMMUNITY; LEUKOCYTE COUNT; MALE; MONOTHERAPY; MOUSE; MYALGIA; NAUSEA; NEUTROPHIL COUNT; NONHUMAN; ORAL MUCOSITIS; OVARY CANCER; PALMAR PLANTAR ERYTHRODYSESTHESIA SYNDROME; PARESTHESIA; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTE COUNT; VOMITING; AGED; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; CLINICAL TRIAL; IMMUNOTHERAPY; MACACA FASCICULARIS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NONOBESE DIABETIC MOUSE; OVARIAN NEOPLASMS; PROCEDURES; SCID MOUSE; WESTERN BLOTTING;

AGED; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZAZEPINES; BLOTTING, WESTERN; DOXORUBICIN; FEMALE; HUMANS; IMMUNOTHERAPY; MACACA FASCICULARIS; MALE; MAXIMUM TOLERATED DOSE; MICE; MICE, INBRED NOD; MICE, SCID; MIDDLE AGED; OVARIAN NEOPLASMS; POLYETHYLENE GLYCOLS; TOLL-LIKE RECEPTOR 8;

EID: 85018813817     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-1453     Document Type: Article

References (35)

1. Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005;202:1691-701.
2. Zitvogel L, Kepp O, Senovilla L, Menger L, Chaput N, Kroemer G. Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res 2010;16:3100-4.
3. Aguilar-Cazares D, Meneses-Flores M, Prado-Garcia H, Islas-Vazquez L, Rojo-Leon V, Romero-Garcia S, et al. Relationship of dendritic cell density, HMGB1 expression, and tumor-infiltrating lymphocytes in non-small cell lung carcinomas. Appl ImmunohistochemMol Morphol 2014;22:105-13.
4. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Tolllike receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007;13:1050-9.
5. Gabrilovich DI,Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012;12:253-68.
6. O'Neill LA, Golenbock D, Bowie AG. The history of Toll-like receptors-redefining innate immunity. Nat Rev Immunol 2013;13: 453-60.
7. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004;5:987-95.
8. Liu J, Xu C, Hsu LC, Luo Y, Xiang R, Chuang TH. A five-amino-acidmotif in the undefined region of the TLR8 ectodomain is required for speciesspecific ligand recognition. Mol Immunol 2010;47:1083-90.
9. Lu H, Dietsch GN, Matthews MA, Yang Y, Ghanekar S, Inokuma M, et al. VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC. Clin Cancer Res 2012;18:499-509.
10. Northfelt DW, Ramanathan RK, Cohen PA, Von Hoff DD, Weiss GJ, Dietsch GN, et al. A phase I dose-finding study of the novel Toll-like receptor 8 agonist VTX-2337 in adult subjects with advanced solid tumors or lymphoma. Clin Cancer Res 2014;20:3683-91.
11. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin Pharmacokinet 2003;42:419-36.
12. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, MassobrioM, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-13.
13. Sato E,Olson SH, Ahn J, Bundy B, NishikawaH,Qian F, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005;102:18538-43.
14. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9.
15. Coleman RL, Monk BJ, Sood AK, Herzog TJ. Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol 2013;10:211-24.
16. Govindaraj RG, Manavalan B, Basith S, Choi S. Comparative analysis of species-specific ligand recognition in Toll-like receptor 8 signaling: a hypothesis. PLoS One 2011;6:e25118.
17. Dietsch GN, Randall TD, Gottardo R, Northfelt DW, Ramanathan RK, Cohen PA, et al. Late-stage cancer patients remain highly responsive to immune activation by the selective TLR8 agonist motolimod (VTX-2337). Clin Cancer Res 2015;21:5445-52.
18. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997;388: 190-5.
19. Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst 2009;101:708-20.
20. Gorden KB, Gorski KS, Gibson SJ, Kedl RM, Kieper WC, Qiu X, et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol 2005;174:1259-68.
21. Tanaka S, Saito Y, Kunisawa J, Kurashima Y, Wake T, Suzuki N, et al. Development of mature and functional human myeloid subsets in hematopoietic stem cell-engrafted NOD/SCID/IL2rgammaKO mice. J Immunol 2012;188:6145-55.
22. Alagkiozidis I, Facciabene A, Tsiatas M, Carpenito C, Benencia F, Adams S, et al. Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy. J Transl Med 2011;9:77.
23. Simpkins F, Flores A, Chu C, Berek JS, Lucci J III, Murray S, et al. Chemoimmunotherapy using pegylated liposomal Doxorubicin and interleukin-18 in recurrent ovarian cancer: a phase I dose-escalation study. Cancer Immunol Res 2013;1:168-78.
24. Alagkiozidis I, Facciabene A, Carpenito C, Benencia F, Jonak Z, Adams S, et al. Increased immunogenicity of surviving tumor cells enables cooperation between liposomal doxorubicin and IL-18. J Transl Med 2009;7:104.
25. Gaur U, Aggarwal BB. Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochem Pharmacol 2003;66: 1403-8.
26. Xiao CW, Yan X, Li Y, Reddy SA, Tsang BK. Resistance of human ovarian cancer cells to tumor necrosis factor alpha is a consequence of nuclear factor kappaB-mediated induction of Fas-associated death domain-like interleukin-1beta-converting enzyme-like inhibitory protein. Endocrinology 2003;144:623-30.
27. Kelly MM, Hoel BD, Voelkel-Johnson C. Doxorubicin pretreatment sensitizes prostate cancer cell lines to TRAIL induced apoptosis which correlates with the loss of c-FLIP expression. Cancer Biol Ther 2002; 1:520-7.
28. Piao X, Komazawa-Sakon S,Nishina T, Koike M, Piao JH, EhlkenH, et al. c-FLIP maintains tissue homeostasis by preventing apoptosis and programmed necrosis. Sci Signal 2012;5:ra93.
29. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011;480:480-9.
30. van der Sluis TC, van Duikeren S, Huppelschoten S, Jordanova ES, Beyranvand Nejad E, Sloots A, et al. Vaccine-induced tumor necrosis factorproducing T cells synergizewith cisplatin to promote tumor cell death.Clin Cancer Res 2015;21:781-94.
31. Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB,Muggia FM, et al. Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J Clin Oncol 2010;28:3107-14.
32. Colombo N, Kutarska E, Dimopoulos M, Bae DS, Rzepka-Gorska I, Bidzinski M, et al. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or-resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer. J Clin Oncol 2012;30:3841-7.
33. Vergote I, Finkler NJ, Hall JB, Melnyk O, Edwards RP, Jones M, et al. Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer. Int J Gynecol Cancer 2010;20:772-80.
34. McDermott D, Lebbe C, Hodi FS, Maio M, Weber JS, Wolchok JD, et al. Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treat Rev 2014;40: 1056-64.
35. Hoos A, Eggermont AM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 2010;102:1388-97.